ATXI Playbook

WEAK CONVICTION • HIGH RISK • LOW LIQUIDITY

ATXI

Avenue Therapeutics, Inc.

CURRENT PRICE (OTC)

$0.27 −15.6%

Last close • Low volume session

Verdict: WATCHLIST ONLY — 0.25–0.5% MAX ALLOCATION

Score: 32/100 • Updated post recent weakness

Probability-Weighted View

Blended Expected Return: +18% to +32%

Probability-weighted Risk/Reward ≈ 1 : 2.1 (only with tiny size)

Bullish: 22% probability → +104% to +141% return

Base / Grind: 43% probability → +26% to +48% return

Bearish: 35% probability → −22% to −41% return

IMPORTANT RISK DISCLAIMER: This is not financial advice. ATXI is a micro-cap OTC biotech stock with extreme volatility, minimal liquidity (often <5k shares/day), and high risk of substantial or total loss. Development-stage companies like Avenue face ongoing dilution risk, clinical/regulatory setbacks, and cash burn. The original playbook levels were set prior to the recent sharp move lower. Past performance and technical setups do not guarantee future results. Only risk capital you can afford to lose entirely. Always do your own due diligence and consult licensed professionals. Position sizing is critical in names like this.

Executive Summary

ATXI remains a low-conviction speculative swing with limited near-term catalysts. The February 2026 licensing of ATX-04 (clenbuterol) for Pompe disease provided a fundamental de-risking event, but the market has since faded the news amid typical micro-cap realities: low float liquidity, no immediate binary catalyst, and broader biotech sector apathy toward early-stage names without clear timelines or funding visibility.

The recent price action (trading \~$0.27) has actually improved the risk/reward profile versus the original 0.35 entry zone. However, conviction stays low because of very thin order book/volume, no visible near-term catalyst, and high probability of continued chop or dilution pressure.

Current Market Snapshot

LAST PRICE

$0.27

−15.6% (recent session)

MARKET CAP

\~$890K

Micro-cap • 3.29M shares

52-WEEK RANGE

$0.15 — $0.97

AVG DAILY VOLUME

\~3,500

Extremely low liquidity — use limit orders

Company Overview & Pipeline Depth

Avenue Therapeutics (OTC: ATXI) is a specialty pharmaceutical company focused on rare and neurologic diseases. It has a very small footprint and limited resources typical of micro-cap biotechs.

Primary Asset — ATX-04 (Clenbuterol)

Repurposed β2-adrenergic agonist licensed exclusively worldwide from Duke University in February 2026 for the treatment of Pompe disease. It is positioned as a potential adjunct to standard-of-care enzyme replacement therapy (ERT), with existing human safety/efficacy data and an active IND + Orphan Drug Designation from Duke’s prior work.

In late 2025 the company sold its Baergic Bio subsidiary to Axsome Therapeutics. The ATX-04 license now represents the main strategic focus.

Original Playbook vs. Current Reality

ORIGINAL (Pre-weakness)

• Entry: $0.35
• Stop: $0.29 (−17.1%)
• T1 / T2: $0.42 (+20%) / $0.55 (+57%)
• R:R blended only \~1:1.3 — thin edge

CURRENT UPDATED VIEW (Post-drop to \~$0.27)

• Entry zone: $0.255 – $0.275 (better R:R)
• Stop: $0.215 – $0.225 (−18% to −20%)
• T1 / T2: $0.38 (+40%) / $0.52–0.55 (+93–104%)
• Improved asymmetric profile if patient

Key Technical Levels

Level Type	Price	% from $0.27	Notes / Context
Strong Support	$0.20 – $0.22	−26% to −19%	Major psychological + volume cluster zone
Entry / Accumulation	$0.255 – $0.275	−6% to +2%	Current suggested zone. Better R:R than original 0.35 entry.
Near-term Resistance	$0.32 – $0.35	+19% to +30%	Original entry zone. First meaningful supply.
Target 1 (Scale-out)	$0.38 – $0.42	+41% to +56%	First scale-out / trim zone
Target 2 (Runner)	$0.52 – $0.58	+93% to +115%	Full runner target on strong catalyst

Scenario Analysis & Probability-Weighted Outcomes

Scenario	Probability	Target Price	% Return	Key Triggers / Notes
Bullish	22%	$0.55 – $0.65	+104% to +141%	Positive clinical update, partnership, or funding news
Base / Grind	43%	$0.34 – $0.40	+26% to +48%	Slow accumulation on low volume, sector sympathy
Bearish	35%	$0.16 – $0.21	−22% to −41%	Continued fade, dilutive financing, or broader selloff

Blended expected return from $0.27 ≈ +18% to +32%. Probability-weighted R:R ≈ 1 : 2.1.

Detailed Trade Execution Plan

Entry Rules

Primary Entry Zone: $0.255 – $0.275 (scale in 40% at 0.27, add on dips to 0.255–0.26). Aggressive add only on volume spike >15k shares and price holding above VWAP.

Exit & Scale-Out Rules

Action	Price Level	% of Position	Rationale
Scale-out (T1)	$0.38 – $0.40	40–50%	Lock meaningful profit
Runner Target (T2)	$0.52 – $0.55	Remainder	Let winner run on momentum
Time-based Exit	—	Full exit	Exit after 25–30 days with no progress
Hard Stop Loss	$0.215 – $0.225	Full exit	Do not move stop lower

Risk Management & Position Sizing

Recommended Allocation

0.25% — 0.5%

Max 0.5% of total portfolio. This is a satellite speculative position only.

Position Rules

• • Use limit orders only — never market orders
• • Pre-define your max $ risk before entry
• • Do not average down below stop
• • Re-evaluate thesis every 2–3 weeks

Catalysts, Timeline & What to Watch

POSITIVE CATALYSTS

• • Late-stage / pivotal study initiation for ATX-04
• • Strategic partnership or licensing deal
• • Non-dilutive funding / grant

NEGATIVE TRIGGERS

• • Dilutive equity offering
• • Clinical development delays
• • Lack of news flow >90 days

MONITORING

IR site & SEC filings weekly • Volume daily • Clinicaltrials.gov monthly

FINAL RECOMMENDATION

Watchlist + Tiny Speculative Position Only

ATXI offers an improved entry point after the recent decline, but the lack of near-term catalysts, extremely low liquidity, and typical micro-cap biotech risks keep overall conviction low. Suitable only for experienced traders who can tolerate high volatility and potential illiquidity on exit.

Max 0.5% portfolio Tight risk controls Re-evaluate in 3–4 weeks

Data as of June 19, 2026. Always verify latest price and news before acting. This is not financial advice.